|
A Trial of Two Steroid Treatments in Premature Infants Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on A Trial of Two Steroid Treatments in Premature Infants conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Trial of Two Steroid Treatments in Premature Infants Clinical research trials and A Trial of Two Steroid Treatments in Premature Infants medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like A Trial of Two Steroid Treatments in Premature Infants. A Trial of Two Steroid Treatments in Premature Infants Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a A Trial of Two Steroid Treatments in Premature Infants clinical trial. Participants frequently obtain the most expert healthcare available for their A Trial of Two Steroid Treatments in Premature Infants condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Trial of Two Steroid Treatments in Premature Infants  A Trial of Two Steroid Treatments in Premature Infants
A Trial of Two Steroid Treatments in Premature Infants
For Condition: Infant, Low Birth Weight,Respiratory Insufficiency,Respiratory Distress Syndrome
Status: Completed
Sponsor(s): National Institute of Child Health and Human Development (NICHD) ,
Synopsis: Infants who are on breathing support are often treated with steroids (dexamethasone); however, the best timing of therapy is not known. This trial looked at the benefits and hazards of starting dexamethasone therapy at two weeks of age and four weeks of age in premature infants.
Details: Ventilator-dependent premature infants are often treated with dexamethasone. However, the optimal timing of therapy is unknown. We compared the benefits and hazards of initiating dexamethasone therapy at two weeks of age and at four weeks of age in 371 ventilator-dependent very-low-birth-weight infants (501 to 1500 grams) who had respiratory-index scores (mean airway pressure x the fraction of inspired oxygen) of greater than or equal 2.4 at two weeks of age. The primary outcome was the number of days from randomization to extubation not requiring reintubation (extubation score or death). The secondary outcomes were death before discharge from the hospital; the duration of assisted ventilation, supplementary oxygen therapy and hospital stay; the incidence of chronic lung disease (defined as the need for supplemental oxygen at 36 weeks postconceptional age by best obstetrical estimate) and rates of morbidity and mortality from respiratory causes during the first year. Additional secondary endpoints were hyperglycemia, hypertension, growth, bacteremia, nectrotizing enterocolitis and upper GI bleeding. The sample size of 370 was based on a 0.60 probability that the extubation score of late treatment was greater than early treatment, a 5% two-sided type 1 error, 85% power, and 10% treatment noncompliance. Infants were randomized to either receive dexamethasone for two weeks followed by saline placebo for two weeks, or saline placebo for two weeks followed by either dexamethasone or additional placebo for two weeks (if they still met entry criteria). Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously or orally for five days, and the dose then tapered. The median time to ventilator independence was 36 days in the dexamethasone-placebo group and 37 days in the placebo-dexamethasone group. The incidences of chronic lung disease (defined as the need for oxygen supplementation at 36 weeks postconceptional age) were 66 percent and 67 percent, respectively. Dexamethasone was associated with an increased incidence of nosocomial bacteremia (relative risk, 1.5; 95 percent confidence interval, 1.1 to 2.1) and hyperglycemia (relative risk, 1.9; 95 percent confidence interval, 1.2 to 3.0) in the dexamethasone-placebo group, elevated blood pressure (relative risk, 2.9; 95 percent confidence interval, 1.2 to 6.9) in the placebo-dexamethasone group, and diminished weight gain and head growth (P less than 0.001) in both groups. Treatment of ventilator-dependent premature infants with dexamethasone at two weeks of age is more hazardous and no more beneficial than treatment at four weeks of age.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Minimum Age/Maximum Age: /15 Days
Genders: Both
Protocol Entry Criteria: Inclusion criteria: - 501 to 1500 grams - 13 to 15 days old - Respiratory-index score of greater than or equal to 2.4 that had been increasing or minimally decreasing during the previous 48 hours or a score of greater than or equal to 4.0 even if there had been improvement during the preceeding 48 hours Exclusion criteria: - Received glucocorticoid treatment after birth - Had evidence or suspicious signs of sepsis as judged by the treating physician - Major congenital anomaly of the cardiovascular, pulmonary, or central nervous system
Total Enrollment: 371
Location and Contact Information:
Overall Study Official:
Lu-AnnPapile, Principal Investigator, University of New Mexico
Additional Information:
Study ID Numbers: NICHD-1010;
Study Start Date: September 1992
Record last reviewed: January 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00011362
Other Respiratory Insufficiency Studies:
1. Farmwork & Preterm Low Birthweight Among Hispanic Women
2. Gluconeogenesis in Very Low Birth Weight Infants Who Are Receiving Nutrition By Intravenous Infusion
3. A Trial of Two Steroid Treatments in Premature Infants
Related Studies:
Other Respiratory Insufficiency Clinical Trials
Other Clinical Trials
Other Clinical Trials
A Trial of Two Steroid Treatments in Premature Infants
|
|
|
|
|
|
|
|
